Laser treatment for hair loss — clinically known as low-level laser therapy (LLLT) or photobiomodulation therapy — is a non-invasive option increasingly sought by people experiencing thinning or shedding hair in the UK. Using specific wavelengths of red or near-infrared light, these devices aim to stimulate hair follicle activity at a cellular level without damaging surrounding tissue. Available through private clinics and as home-use devices, LLLT is most commonly applied to androgenetic alopecia. This article explains how it works, what the evidence shows, safety considerations, how to access treatment in the UK, and how it compares with other established hair loss therapies.

What Is Laser Treatment for Hair Loss?

Laser treatment for hair loss (LLLT) uses red or near-infrared light to stimulate mitochondrial activity in hair follicle cells, promoting a shift from the resting to active growth phase; it is most evidence-based for androgenetic alopecia and does not regenerate permanently destroyed follicles.

Not sure if this is normal? Chat with one of our pharmacists →

Laser treatment for hair loss — also referred to as low-level laser therapy (LLLT) or photobiomodulation therapy — is a non-invasive intervention that uses specific wavelengths of light to stimulate hair follicle activity. Unlike surgical hair restoration or ablative laser procedures, LLLT does not damage tissue. Instead, it works at a cellular level to encourage follicular function in areas affected by thinning or shedding.

The proposed mechanism of action centres on the absorption of red light (typically in the 630–680 nanometre range) or near-infrared light (commonly 780–1100 nm) by mitochondria within hair follicle cells. This is thought to increase the production of adenosine triphosphate (ATP), reduce oxidative stress, and promote a shift from the telogen (resting) phase of the hair growth cycle back into the anagen (active growth) phase. The result, in theory, is improved follicular metabolism and, over time, increased hair density and thickness. It is important to note that these benefits generally require ongoing use to maintain, and a proportion of users do not respond to treatment.

LLLT is most commonly used for androgenetic alopecia — the pattern hair loss that affects both men and women — and this is where the strongest, albeit still modest, evidence exists. It is also being explored for other forms of hair loss, including alopecia areata and chemotherapy-induced alopecia; however, evidence for these indications is limited and should be considered investigational at this stage. Laser treatment does not regenerate follicles that have been permanently destroyed; it works best when some follicular activity remains.

Patients considering this option should seek a thorough clinical assessment — ideally with their GP or a consultant dermatologist — to confirm the underlying cause of their hair loss before commencing any treatment. Sudden or rapidly accelerating hair loss, scalp scaling, patchy loss with broken hairs, or hair loss accompanied by systemic symptoms (such as fatigue, weight change, or joint pain) should prompt prompt medical review, as these may indicate conditions requiring specific investigation and treatment.

Types of Laser Devices Used in the UK

UK laser hair loss devices range from in-clinic helmets and panels to home-use laser combs and caps; all must carry a valid UKCA or CE mark under MHRA regulations, and consumers should verify that true laser diodes — not LEDs — are used where specified.

In the UK, laser hair loss devices are available across a spectrum of clinical and consumer settings. They broadly fall into two categories: in-clinic devices operated by trained practitioners, and home-use devices that individuals can purchase and use independently.

In-clinic options typically include:

• Laser helmets and hoods — large devices that deliver uniform light exposure across the entire scalp simultaneously.

• Laser combs and panels — handheld or fixed units used by practitioners during scalp treatment sessions.

• Combination devices — some clinics offer LLLT alongside other modalities such as microneedling or platelet-rich plasma (PRP) therapy.

Home-use devices have grown considerably in popularity and include laser combs, caps, and helmets. It is worth noting that true laser diodes and light-emitting diodes (LEDs) are not identical in their output, and some products marketed as 'laser' devices may rely primarily on LED technology. Consumers should verify the device specifications carefully, as the evidence base for LEDs and true laser diodes may not be directly interchangeable.

All medical devices sold in the UK must comply with regulations overseen by the Medicines and Healthcare products Regulatory Agency (MHRA). Under current MHRA transitional arrangements, devices carrying a valid CE mark continue to be accepted for sale in Great Britain alongside those bearing a UKCA mark; consumers should check which marking applies and confirm that the manufacturer or UK Responsible Person details are clearly stated and that instructions are provided in English. Consumers are advised to be cautious of unregistered or unmarked products sold through informal online channels, which may not meet UK safety requirements. The MHRA does not individually approve devices in the way medicines are licensed; rather, it oversees market surveillance and conformity assessment processes.

If you experience a problem with a medical device, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

What the Evidence Says About Effectiveness

Randomised controlled trials and meta-analyses show statistically significant but modest improvements in hair count and density for androgenetic alopecia with LLLT; long-term data beyond 12 months are limited, non-responders are common, and NICE has not issued specific guidance.

The evidence base for laser treatment for hair loss has grown over the past two decades, though it remains of moderate quality overall. Several randomised controlled trials (RCTs) and systematic reviews — including a widely cited meta-analysis published in the Journal of the American Academy of Dermatology (Adil & Godwin, 2017) — have demonstrated statistically significant improvements in hair count and density in individuals with androgenetic alopecia following LLLT, compared with sham devices. Subsequent systematic reviews have broadly supported these findings, though effect sizes are generally modest.

However, several important limitations should be acknowledged:

• Heterogeneity across studies in terms of device type, wavelength, treatment duration, and outcome measures makes direct comparison difficult.

• Risk of bias, including industry sponsorship of some trials, should be considered when interpreting results.

• Placebo effects can be challenging to control for in hair loss research.

• Long-term data beyond 12 months remain limited, and benefits are generally sustained only with continued, ongoing use. Cessation of treatment is likely to result in a return to the pre-treatment trajectory.

• Non-responders are common; not all individuals will experience meaningful benefit.

• Most studies focus on androgenetic alopecia; evidence for other hair loss conditions is considerably weaker.

At present, NICE has not issued specific guidance on LLLT for hair loss, and it is not routinely commissioned by the NHS. The treatment is therefore considered an elective, self-funded option for most patients in the UK. Clinicians and patients should approach efficacy claims with measured expectations — LLLT may slow progression and modestly improve density, but it is unlikely to produce dramatic regrowth, particularly in advanced cases. Realistic goal-setting during the initial consultation is essential.

Safety Considerations and Possible Side Effects

LLLT is generally safe when used correctly, with side effects typically mild and transient — including scalp warmth, temporary shedding, and mild irritation; direct eye exposure must be avoided, and those on photosensitising medicines should seek GP advice before use.

Experiencing these side effects? Our pharmacists can help you navigate them →

Laser treatment for hair loss is generally regarded as a safe intervention when devices are used correctly and in accordance with manufacturer guidelines. Because LLLT operates at low energy levels and does not generate significant heat, the risk of thermal injury to the scalp is minimal with properly regulated devices.

Reported side effects are typically mild and transient. These may include:

• Scalp warmth or tingling during or immediately after treatment.

• Temporary increase in shedding in the early weeks of treatment — this is thought to reflect a shift in the hair cycle and is usually self-limiting.

• Mild scalp irritation, dryness, or contact dermatitis, particularly with prolonged or frequent use.

• Headache, which has been reported in some users.

• Eye safety concerns — direct exposure of the eyes to laser light should always be avoided; most devices include protective measures, but users should follow instructions carefully.

Serious adverse events are uncommon with regulated devices used as directed, but can occur. If you experience significant scalp reactions, burns, or other unexpected effects, stop use and seek medical advice promptly. Suspected adverse effects or device problems should be reported to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

Individuals with photosensitive conditions, or those taking photosensitising medicines — such as tetracyclines, thiazide diuretics, amiodarone, St John's Wort, or systemic or topical retinoids — should seek advice from their GP or pharmacist before commencing treatment, as these may increase the risk of skin reactions. LLLT should not be used over areas of known or suspected skin cancer, suspicious scalp lesions, or active scalp infections or inflammatory skin conditions until these have been assessed and appropriately managed.

Patients should be advised to contact their GP or a dermatologist if they experience:

• Sudden or rapidly accelerating hair loss, which may indicate an underlying medical cause requiring investigation.

• Signs that may suggest scarring alopecia (such as scalp redness, scaling, or follicular changes), which requires specialist assessment.

• Persistent scalp pain, redness, or signs of infection.

• No improvement after six months of consistent use, prompting reassessment of diagnosis and treatment strategy.

Pregnant women are generally advised to avoid LLLT until further safety data are available, as robust evidence in this population is lacking.

Accessing Laser Hair Loss Treatment in the UK

Laser hair loss treatment is not available on the NHS for androgenetic alopecia and must be accessed privately, either through consultant dermatologists, trichology clinics, or home-use devices carrying a valid UKCA or CE mark; a GP assessment to exclude underlying causes is advisable first.

In the UK, laser treatment for hair loss is not available on the NHS for cosmetic hair loss conditions such as androgenetic alopecia. Patients seeking this treatment will typically need to access it through the private sector. There are several routes available:

GP or dermatologist assessment first — Before pursuing any hair loss treatment, it is advisable to consult your GP to confirm the diagnosis and exclude treatable underlying causes, such as thyroid dysfunction, iron deficiency, or autoimmune conditions. Your GP can refer you to an NHS or private consultant dermatologist if specialist assessment is needed.

Private dermatology or trichology clinics — A consultation with a consultant dermatologist or a trichologist (a specialist in scalp and hair health) can provide a thorough assessment and treatment planning. The Institute of Trichologists and the Trichological Society maintain voluntary registers of practitioners in the UK. It is important to note that trichology is not a statutorily regulated profession in the UK; membership of these professional bodies is voluntary. Patients should check practitioner credentials and scope of practice carefully. For doctors, registration can be verified via the General Medical Council (GMC) online register.

Hair restoration clinics — Many private clinics offering surgical hair transplantation also provide LLLT as a standalone or adjunctive treatment. Standards of care can vary; patients are encouraged to verify practitioner qualifications and, for clinics offering surgical procedures, to check registration with the Care Quality Commission (CQC) using the CQC 'Find a provider' service. Membership of professional bodies such as the British Association of Hair Restoration Surgery (BAHRS) may also provide reassurance.

Home-use devices — For those who prefer a self-directed approach, home laser devices are widely available online and in specialist retailers. Costs vary considerably, ranging from approximately £200 to over £800 for devices from established manufacturers. Patients should ensure the device carries a valid UKCA or CE mark, with clear manufacturer or UK Responsible Person details, and should ideally discuss suitability with a healthcare professional beforehand. Be cautious of unmarked or unregistered products sold through informal online channels.

Costs for in-clinic LLLT sessions typically range from £50 to £150 per session, with courses of treatment often recommended over several months. These figures are indicative only and prices vary widely. Patients should request a clear treatment plan and realistic outcome expectations before committing financially.

Comparing Laser Therapy With Other Hair Loss Treatments

LLLT is a non-invasive, well-tolerated adjunct to treatments such as topical minoxidil and finasteride, but lacks the strong standalone evidence of these licensed therapies; the optimal approach depends on hair loss type, severity, and individual health factors.

When considering laser treatment for hair loss, it is helpful to understand how it compares with other established and emerging options available in the UK. No single treatment suits every patient, and the optimal approach often depends on the type and severity of hair loss, individual health factors, and personal preference.

Minoxidil is one of the most widely used treatments for androgenetic alopecia and is endorsed within NICE Clinical Knowledge Summaries. Topical minoxidil (available over the counter as a solution or foam) is the licensed formulation for pattern hair loss in the UK. It works by prolonging the anagen phase and increasing follicular size, and requires ongoing daily application to maintain results; some users experience initial shedding or scalp irritation. Oral minoxidil for hair loss is off-label in the UK and should only be initiated and monitored by an appropriately qualified clinician; potential risks include hypotension, tachycardia, fluid retention, and unwanted body hair growth (hypertrichosis).

Finasteride (oral, prescription-only for men) inhibits the conversion of testosterone to dihydrotestosterone (DHT), the androgen primarily responsible for follicular miniaturisation in male pattern baldness. It has strong clinical evidence for men. Finasteride is not indicated for use in women; women who are pregnant or may become pregnant must not handle crushed or broken tablets due to the risk of harm to a male foetus. The MHRA issued updated safety advice in 2024 highlighting the risk of psychiatric adverse effects (including depression, anxiety, and suicidal thoughts) and persistent sexual dysfunction (including after stopping treatment). Patients should be counselled about these risks before starting treatment and advised to seek urgent medical help if they experience mood changes, thoughts of self-harm, or persistent sexual side effects. A patient information card is available from the prescriber.

Platelet-rich plasma (PRP) therapy involves injecting concentrated growth factors derived from the patient's own blood into the scalp. Evidence is promising but not yet conclusive, and it is also self-funded in the UK.

Surgical hair transplantation (FUE or FUT techniques) offers long-lasting results for suitable candidates but is invasive, costly, and not appropriate for all hair loss patterns. Transplanted hairs may be subject to ongoing miniaturisation over time, and many patients require continued medical therapy to preserve native hair.

LLLT occupies a useful niche as a non-invasive, well-tolerated adjunct to other treatments. Many clinicians suggest combining LLLT with topical minoxidil or finasteride for a potentially synergistic effect, though robust combination-therapy trial data remain limited. A personalised, evidence-informed approach — ideally guided by a qualified specialist — remains the gold standard.

Frequently Asked Questions